# The Plant Alkaloid Harmaline Blocks the Voltage-Gated Sodium Channel Nav1.7: A Study Using an Automated Patch-Clamp

## TL;DR

This study shows that harmaline, a compound from a North African plant, effectively blocks a sodium channel involved in pain perception, suggesting potential for new pain treatments.

## Contribution

The study demonstrates that harmaline is a voltage-independent blocker of Nav1.7, offering a novel pharmacological approach for pain management.

## Key findings

- Harmaline inhibits both peak and late Na+ currents with half-maximum inhibition at 35.5 µM.
- The effect of harmaline on Nav1.7 is voltage independent, unlike the drug ranolazine.
- Harmaline is an effective blocker of Nav1.7, supporting its potential use in treating pain syndromes.

## Abstract

The voltage-gated sodium channel Nav1.7 is essential for pain perception and is an interesting target for the development of pain-relieving substances. Here, we investigated whether the Nav1.7 channel is sensitive to harmaline, an alkaloid produced by the North African plant Peganum harmala. To this end, we used Chinese hamster ovary (CHO) cells expressing the human Nav1.7 channel and studied Na+ channel pharmacology with an automated patch-clamp technique. Cells stimulated with depolarizing voltage pulses responded with typical transient inward currents. The Na+ channel blocker ranolazine inhibited whole-cell currents in a concentration-dependent manner (IC50: 12.1 µM). Harmaline inhibited both peak and late Na+ currents. A complete block was achieved at 300 µM of harmaline, with half maximum inhibition occurring at 35.5 µM. In contrast to ranolazine, the effect of harmaline was voltage independent. Neither the current/voltage curves nor the steady-state inactivation curves were shifted in response to drug application (30 µM). We conclude that the plant alkaloid harmaline, which is used in traditional medicine in North Africa, is an effective blocker of the voltage-gated Na+ channel Nav1.7. Our results offer a rationale for the use of harmaline against certain pain syndromes and rise hopes for the development of a new class of anti-nociceptive drugs targeting Nav1.7.